GlassScriptPhysician profile
Fabian E Alzamora
NPI 1073528832
$609.16
in general payments reported to CMS, 2019-2025
13 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35.87 · 2020: $40.18 · 2021: $86.51 · 2022: $86.88 · 2023: $103 · 2024: $61.88 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tela Bio, INC. | $195.00 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Stryker Corporation | $88.17 | 2023 | 1688 |
| Davol INC. | $86.51 | 2021 | |
| Integra Lifesciences Corporation | $43.33 | 2020-2022 | |
| Boston Scientific Corporation | $30.30 | 2023-2024 | Spyglass Discover, Spyglass |
| Teleflex LLC | $26.58 | 2022 | |
| Abbott Laboratories | $23.22 | 2024 | Eterna |
| Heron Therapeutics, INC. | $23.03 | 2024 | Zynrelef |
| Hologic INC | $21.75 | 2022 | |
| Merck Sharp & Dohme LLC | $21.18 | 2022 | |
| Covidien LP | $20.12 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.75 | 2019 | |
| Smith+Nephew, INC. | $14.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabian Alzamora listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.